RAC

0.60%

$1.69 race oncology ltd

Ann: Zantrene AML trial in Israel advances to Phase 2, page-125

First 125 Last

Share
Profile

Follow
ma420

7,060 Posts.

1807

15/07/23

08:19

Post #: 68800533
Share

Originally posted by Davisite: ↑

The 505(b)(2) pathway just allows you to include outside clinical studies as part of your data package. To do this these external studies have to be comparable to your studies. If the historical studies were all single agent studies and your studies are all combination studies then they are not comparable.

While the Sheba study provides interesting clinical data on bisantrene (especially its ability to work in highly pretreated and refractory AML patients), it is not on any approval pathway.

The biggest value Sheba provides is demonstrating that bisantrene is still relevant in a modern context. For many investors the historical data is interesting (to some of us it is more than interesting), but it is not the same as knowing that bisantrene still works despite patients having much more treatment options today. In the past (1980s) AML patients had one treatment option and then it was onto at most one experimental treatment. Today AML patients have hundreds of experimental options and patients are reaching 7,8, or even 9 prior lines of treatment. If a drug works after 1 prior line of treatment is very different than if it works after 8 prior lines of treatment.

Expand

Can you please explain why you say that AML is not an approval pathway? What does it mean from the perspective of doing phase 3 trials and possible M&A for AML?

RAC Price at posting: $1.60 Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

MLS

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

VUL

Vulcan appoints investment bank and M&A veteran to board

NAM

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

MM8

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

AZY

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

ENV

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

ASN

Utah authorities sign off on Anson's lithium extraction plans at Green River

MKG

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

There are more pages in this discussion • 109 more messages in this thread...

First 125 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.69		Change 0.010(0.60%)		Mkt cap ! $287.1M

Open	High	Low	Value	Volume
$1.69	$1.70	$1.65	$89.01K	53.2K

Buyers (Bids)

No.	Vol.	Price($)
1	2342	$1.69

Sellers (Offers)

Price($)	Vol.	No.
$1.70	5	1

View Market Depth

No.	Vol.	Price($)
1	2342	1.685
1	3664	1.680
1	5077	1.660
1	1265	1.650
1	612	1.635

Price($)	Vol.	No.
1.695	5	1
1.700	11000	1
1.730	2399	1
1.750	952	2
1.775	1328	1

Last trade - 16.10pm 13/09/2024 (20 minute delay)

RAC (ASX) Chart

Ann: Zantrene AML trial in Israel advances to Phase 2, page-125

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Vulcan appoints investment bank and M&A veteran to board

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Utah authorities sign off on Anson's lithium extraction plans at Green River

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Zantrene AML trial in Israel advances to Phase 2, page-125

Top Stories

Metals Australia kicking off plant study at Lac Carheil; Canadian tariff tailwind potential

Vulcan appoints investment bank and M&A veteran to board

Olam Agri raises Namoi takeover offer to 75 cents a share and receives shareholder backing

Medallion Metals kicking off 15,000m drill run at Ravensthorpe gold play

Week 37 Wrap: HotCopper likes Cuban oil; markets shrug debate off for Putin; firebrand quant says social media a market threat

Antipa divests its Citadel interest to JV partner Rio for A$17M, refocuses on Minyari Dome

Dale Gillham's weekly wrap: US fracking support boosts outlook for Australian gas stocks

Enova Mining unveils "high-grade" REE drill hits at Coda North, Brazil

Utah authorities sign off on Anson's lithium extraction plans at Green River

Mako sniffs gold at 170 g/t at Cote d’Ivoire's Napié play

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News